Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MP3•Home de episódios
Manage episode 437205558 series 3382903
Conteúdo fornecido por ReachMD. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por ReachMD ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
…
continue reading
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
604 episódios